Pancreatic Cancer Trials

To go back to the main page, click here

				Current		Start	Completion	
S.No.	Drug Name	Biological Name	Developer	Development Phase	Additional Information	Date	Date	Source
11	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	<u>Source</u>
12	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	<u>Source</u>
13	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	-	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	Source
14	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	Source
15	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	_	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	Source
16	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	Source
17	HyperAcute Pancreas	-	NewLink Genetics	II	The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.	2010	2014	Source
18		HyperAcute(R)-Pancreatic Cancer Vaccine	NewLink Genetics	II	To assess the response for subjects with pancreatic cancer that	2007	2011	Source

					have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.			
19	cyclophosphamide	GVAX pancreatic cancer vaccine	Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI)		This randomized clinical trial is studying the side effects of vaccine therapy and to see how well it works when given with or without cyclophosphamide in treating patients undergoing chemotherapy and radiation therapy for stage I or stage II pancreatic cancer that can be removed by surgery.	2008	2012	<u>Source</u>
20	Ipilimumab	PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine	Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI)	-	To determine the safety profile of ipilimumab alone or in combination with a pancreatic cancer vaccine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.	2009	2011	<u>Source</u>
21	-	GI-4000 Vaccine + Activated T Cells, Surgical Evaluation after Vaccine 4	University of Pennsylvania	I	The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be completely removed by surgery	2008	2009	<u>Source</u>

To go back to the main page, click here